Recombinant Anti-BRMS1 antibody [EPR7202] (ab134968)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7202] to BRMS1
- Suitable for: WB, IHC-P, ICC/IF, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-BRMS1 antibody [EPR7202]
See all BRMS1 primary antibodies -
Description
Rabbit monoclonal [EPR7202] to BRMS1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IF, IPmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human BRMS1 (N terminal). The exact sequence is proprietary.
-
Positive control
- WB: HeLa, 293T, HepG2, and Human colon cancer lysates; IHC: Human colon and placenta tissues; ICC: HepG2 cells. IP: HeLa.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7202 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134968 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 28 kDa (predicted molecular weight: 28 kDa).
|
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
ICC/IF |
1/250 - 1/500.
|
|
IP |
1/10 - 1/100.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 28 kDa (predicted molecular weight: 28 kDa). |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
1/250 - 1/500. |
IP
1/10 - 1/100. |
Target
-
Function
Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. -
Tissue specificity
Expression levels are higher in term placentas than in early placentas. Low levels of expression observed in normal pregnancies and in molar pregnancies. -
Sequence similarities
Belongs to the BRMS1 family. -
Cellular localization
Nucleus. Cytoplasm. Predominantly nuclear. - Information by UniProt
-
Database links
- Entrez Gene: 25855 Human
- Omim: 606259 Human
- SwissProt: Q9HCU9 Human
- Unigene: 100426 Human
-
Alternative names
- AV003220 antibody
- AW554636 antibody
- Breast cancer metastasis suppressor 1 antibody
see all
Images
-
All lanes : Anti-BRMS1 antibody [EPR7202] (ab134968) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : 293T cell lysate
Lane 3 : HepG2 cell lysate
Lane 4 : Human colon cancer lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 28 kDa
Observed band size: 28 kDa -
Immunofluorescence staining of HepG2 cells with purified ab134968 at a working dilution of 1/1000, counter-stained with DAPI. The secondary antibody was an Alexa Fluor® 488 conjugated goat anti-rabbit (ab150077), used at a dilution of 1/1000. The cells were fixed in 4% PFA and permeabilized using 0.1% Triton X 100. The negative control is shown in bottom right hand panel - for the negative control, PBS was used instead of the primary antibody.
-
BRMS1 was immunoprecipitated from 0.35 mg HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10 µg with 134968 at 1/50 dilution (2µg). VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10 µg
Lane 2: ab134968 IP in HeLa whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab134968 in HeLa whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
-
Immunohistochemical analysis of paraffin-embedded Human colon tissue labelling BRMS1 with ab134968 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Imunohistochemical analysis of paraffin-embedded Human placenta tissue labelling BRMS1 with ab134968 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemical analysis using ab134968 showing positive staining in Ovarian carcinoma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemical analysis using ab134968 showing positive staining in Breast carcinoma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (14)
ab134968 has been referenced in 14 publications.
- Zhou C et al. N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine 59:102955 (2020). PubMed: 32853985
- Yang L et al. Anti-tumor peptide SA12 inhibits metastasis of MDA-MB-231 and MCF-7 breast cancer cells via increasing expression of the tumor metastasis suppressor genes, CDH1, nm23-H1 and BRMS1. Exp Ther Med 20:1758-1763 (2020). PubMed: 32742405
- Xiong J et al. Epigenetics mechanisms mediate the miR-125a/BRMS1 axis to regulate invasion and metastasis in gastric cancer. Onco Targets Ther 12:7513-7525 (2019). PubMed: 31571904
- Wu Y et al. BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients. Onco Targets Ther 12:6937-6945 (2019). PubMed: 31695409
- Bucciarelli PR et al. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84 (2018). IHC-P . PubMed: 29097253